MV interview on A usbiz, page-7

there will be two more CR.s.. if everyone wants immutep to run to the post solo that is what will be required... yes dilution... but the revenue from dividends will far out weight the short term dance of the capital requirements... (or pain to some....)

everyone is focused on cancer at the moment, LAG 3 is still in play for immutep as Freedy T is the OG of this Tech... but it is open season on this tech the license for it is now open (season)... first in class first to market... it will be the auto immune conditions that will pave the way for long term sleepy but important improvement in public health outcomes.... immutep has a stable of products... if the tech is safe in the battle against cancer then everything else is a walk in the park............

grab a calculator and look at the budgets of society with just the management of 1 of the top 100 hundred auto immune conditions.... namely diabetes.

just for the tits booom...